Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Low dose versus high dose imatinib for gastrointestinal stromal tumors

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65

    Article  CAS  Google Scholar 

  2. Rankin C et al. (2004) Dose effect of imatinib in patients with metastatic GIST: Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 22: 819

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charles Blanke.

Ethics declarations

Competing interests

Charles Blanke receives research support from Novartis.

Glossary

BCR-ABL

A tyrosine kinase arising from the product of reciprocal translocation of chromosomes 9 and 22

KIT

The protein product of the c-KIT gene; GIST are characterized by c-KIT expression

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blanke, C. Low dose versus high dose imatinib for gastrointestinal stromal tumors. Nat Rev Gastroenterol Hepatol 2, 76–77 (2005). https://doi.org/10.1038/ncpgasthep0086

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0086

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing